We next used the TMD8 cell line, an ABC-DLBCL line that harbors an oncogenic Y196H mutation in the B cell receptor CD79B subunit that confers dysregulated CBM-mediated NF-κB signaling (43), to test the ability of M1i-124 and M1i-124d1 to inhibit MALT1 protease and scaffolding functions in the context of constitutive MALT1 activation. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.